In the last trading session, 12.87 million shares of the ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) were traded, and its beta was 0.24. Most recently the company’s share price was $0.58, and it changed around -$0.1 or -15.09% from the last close, which brings the market valuation of the company to $14.36M. IPA currently trades at a discount to its 52-week high of $2.60, offering almost -348.28% off that amount. The share price’s 52-week low was $0.46, which indicates that the current value has risen by an impressive 20.69% since then. We note from ImmunoPrecise Antibodies Ltd’s average daily trading volume that its 10-day average is 1.63 million shares, with the 3-month average coming to 219.09K.
ImmunoPrecise Antibodies Ltd stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended IPA as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. ImmunoPrecise Antibodies Ltd is expected to report earnings per share of -0.07 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) trade information
Instantly IPA has showed a red trend with a performance of -15.09% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.6950 on recent trading dayincreased the stock’s daily price by 16.55%. The company’s shares are currently down -66.33% year-to-date, but still up 7.59% over the last five days. On the other hand, ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) is -11.07% down in the 30-day period. We can see from the shorts that 0.15 million shares have been sold at a short interest cover period of 0.45 day(s).
ImmunoPrecise Antibodies Ltd (IPA) estimates and forecasts
ImmunoPrecise Antibodies Ltd share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -57.97 percent over the past six months and at a 61.54% annual growth rate that is well above the industry average of 23.90%. The year-over-year growth rate is expected to be 0.50%, up from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 4.63M in revenue for the current quarter. 2 analysts expect ImmunoPrecise Antibodies Ltd to make 4.83M in revenue for the current ending quarter.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -11.23%.
IPA Dividends
ImmunoPrecise Antibodies Ltd’s next quarterly earnings report is expected to be released in November.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 12.73% of ImmunoPrecise Antibodies Ltd shares, and 6.07% of them are in the hands of institutional investors. The stock currently has a share float of 6.96%. ImmunoPrecise Antibodies Ltd stock is held by 22.0 institutions, with INGALLS & SNYDER LLC being the largest institutional investor. By 2024-06-30, it held 5.0209% of the shares, which is about 1.3 million shares worth $1.31 million.
RENAISSANCE TECHNOLOGIES LLC, with 0.2477% or 63910.0 shares worth $64549.0 as of 2024-06-30, holds the second largest percentage of outstanding shares.
